Moosa Mubarika

Dr. Moosa Mubarika

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 April 2026 in Neurological Sciences
Verified
Journal Article
Open access
PDF file
JFJawaria Firdous
Jawaria Firdous
AAAbdul Eizad Asif
Abdul Eizad Asif
HHHafiz Muhammad Haris
Hafiz Muhammad Haris
UIUzair Iqbal
Uzair Iqbal
MKMuddassir Khalid
Muddassir Khalid
AHAnid Hassan
Anid Hassan
Purpose: Glioblastoma (GBM) remains the most common and lethal primary central nervous system tumor, with a median survival of only 14.6 months under standard care. The tumor’s characteristic "Warburg effect"—a dependency on aerobic glycolysis for energy—creates a metabolic vulnerability. This review evaluates the efficacy and safety of the ketogenic diet (KD) as an adjunctive metabolic therapy aimed at exploiting this glucose dependency. Methods: This PRISMA-compliant systematic review updates clinical evidence by synthesizing data from databases from 2000 to September 2025. We searched PubMed, Embase, Cochrane, and Web of science for human studies assessing the ketogenic diet (KD) in glioblastoma and high-grade gliomas. Primary outcomes included overall survival (OS), progression-free survival (PFS), feasibility, and adverse events. Study quality was assessed using Joanna Briggs Institute tools. Prospero registration: CRD420251232650. Results: Forty-one studies were included, ranging from randomized trials to case series and abstracts, utilizing interventions such as the classic 4:1 ketogenic diet, Modified Atkins Diet, and calorie restriction. Adherence was high (> 75% maintained nutritional ketosis). Recent data indicate significant survival benefits; adherent cohorts achieved a median OS of 29.4 months vs 14.6 months in historical controls; with 66.7% 3-year survival rate. The diet was well-tolerated, with adverse events limited to mild gastrointestinal symptoms and fatigue. No Grade 3/4 diet-related toxicities reported. Conclusion: Current evidence supports the KD as a safe, feasible, and biologically rational adjunct to standard glioblastoma treatment. It demonstrates potential to prolong survival without severe toxicity, highlighting the need for standardized Phase III trials to establish clinical guidelines.

18 May 2026 in Cancers
Verified
Journal Article
Open access
PDF file
BABiruk Demisse Ayalew
Biruk Demisse Ayalew
MHMuhammad Areeb Ul Haq
Muhammad Areeb Ul Haq
TFTalha Farooq
Talha Farooq
Moosa MubarikaMoosa Mubarika
Moosa Mubarika
MUMuhammad Umar
Muhammad Umar
DADaniel Addison
Daniel Addison
Cardiovascular toxicity has emerged as a major determinant of long-term outcomes in cancer survivors as advances in oncologic therapies continue to improve survival. Conventional cardiac surveillance strategies predominantly rely on functional and structural changes, often identifying myocardial injury after clinically significant damage has occurred. The aim of this narrative review is to critically evaluate the role of nuclear imaging in advancing precision cardio-oncology by enabling earlier, mechanism-based detection and characterization of cancer therapy-related cardiotoxicity. We summarize current clinical applications of PET- and SPECT-based imaging, examine molecular and tracer-level innovations, and discuss emerging hybrid imaging and analytic approaches relevant to individualized cardiovascular risk stratification. Current literature indicates that nuclear imaging provides unique insights into myocardial perfusion, metabolism, inflammation, and microvascular dysfunction, facilitating detection of subclinical injury across diverse anticancer therapies, including anthracyclines, targeted agents, and immune checkpoint inhibitors. By integrating molecular imaging with conventional modalities, nuclear techniques support more personalized surveillance and management strategies. This narrative review highlights nuclear imaging as an emerging complementary modality within precision cardio-oncology supporting earlier detection and risk stratification, and outlines future directions required to optimize its clinical integration and impact on cardiovascular outcomes across the cancer care continuum.


24 August 2026 in BMC Pediatrics
Verified
Journal Article
Open access
PDF file
Moosa MubarikaMoosa Mubarika
Moosa Mubarika
OFOmer Farooq
Omer Farooq
SGSyed Assar Imam Gardezi
Syed Assar Imam Gardezi
MAMuhammad Abdullah
Muhammad Abdullah
ARAbdul Rehman
Abdul Rehman
MSMuhammad Hussnain Sadiq
Muhammad Hussnain Sadiq
Oral iron supplementation is the first-line therapy for pediatric iron deficiency anemia (IDA). Ferrous sulphate (FS) remains the conventional standard of

25 August 2026 in Clinical and Translational Imaging
Verified
Journal Article
Closed access
PDF file
Moosa MubarikaMoosa Mubarika
Moosa Mubarika
MMMuhammad Maaz
Muhammad Maaz
BABiruk Demisse Ayalew
Biruk Demisse Ayalew
Ali Shan HafeezAli Shan Hafeez
Ali Shan Hafeez
ZBZineddine Belabaci
Zineddine Belabaci
Giorgio TregliaGiorgio Treglia
Giorgio Treglia